Clinical application of second generation GCMAF and colostrum MAF as cancer therapy

---

Shinichiro Akiyama

Saisei Mirai Clinic, Japan

: J Regen Med

Abstract

---

In recent years, immunotherapy has become an attractive new strategy not only in the treatment of cancer but also in the treatment of many other acute and chronic diseases. Macrophages are phagocytic cells that plays an important role in innate immune system. Macrophage activating therapy such as Gc protein derived macrophage activating factor (Gc-MAF) has wide application for use in miscellaneous diseases by activating macrophages to stimulate the immune system. GcMAF immunotherapy has been steadily advancing in the last decade. Saisei Mirai developed a powerful new and more stable 2nd generation GcMAF in collaboration with Tokushima University in 2010. In 2014, Saisei Mirai succeeded in developing and manufacturing a new oral form of MAF from bovine colostrum. Colostrum MAF is administered orally in an enteric capsule, which is meant to activate macrophages directly in the Gut-Associated Lymphoid Tissue (GALT). We demonstrated that both forms have high macrophage phagocytic activity. The general goals of GcMAF and oral colostrum-MAF immunotherapy are to improve well-being and quality of life (QOL), return the patient to good health so that they are able to participate in regular life-style activities, achieve long-term survival and enhance the effect of other therapies. This is achieved by repairing the immune system by activating macrophages to destroy cancer cells, viruses, bacteria and other pathogens in the body. Methods: The standard protocol of our integrative cancer therapy includes GcMAF administered subcutaneously two or more times per week with colostrum-MAF administered orally and sublingually, daily for the duration of cancer therapy, in combination with vitamin D3 and other complementary therapies such as gene therapy, high dose vitamin C and sonophotodynamic therapy. Results: We emphasize the important roles of GcMAF in cancer immunotherapy via macrophage activation and how it is used in an integrative treatment setting, showing some case reports. Conclusion: GcMAF-based immunotherapy can be combined with many other therapies. We demonstrate the use of GcMAF in combination with other therapies to treat cancer patients and treat a wide variety of symptoms. Importantly, colostrum-MAF shows promising clinical results in patients with infectious diseases and for symptoms of fatigue, which are common in many cancer patients and an important application of GcMAF improves QOL and outcomes for patients.

Biography

---

Shinichiro Akiyama currently is general director of the Saisei Mirai Clinic in Tokyo, Japan. Saisei Mirai Clinic is one of the most comprehensive innovative cancer therapy centers in Asia. He had been a fellow in oncology at Sapporo Medical University School of Medicine. This led to clarify intracellular TNF as a resistant factor by chemotherapeutic agents. He joined the Cancer Immune Cell Therapy Center of Kudan Clinic in 2009.

E-mail: akiyamafirst@icloud.com